An antibody (Ab), also known as an immunoglobulin (Ig), is secreted by B cells of the adaptive immune system, mostly by differentiated B cells called plasma cells. Antibodies are used in the treatment of various cancers and other diseases such as rheumatoid arthritis and psoriasis.
Statistics:
The global antibodies market is estimated to account for US$ 147,385.1 Mn in terms of value and is expected to reach US$ 384,011.6 Mn by the end of 2027.
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2629
Global Antibodies Market: Drivers
Increasing demand for antibody-drug conjugates (ADCs) is expected to propel growth of the global antibodies market over the forecast period. ADCs use monoclonal antibodies to specifically bind tumour-associated target antigens and deliver a highly potent cytotoxic agent. This has led to increasing adoption of ADCs for the treatment of cancer.
Global Antibodies Market: Opportunities
Major players in the market can focus on expanding their presence in Africa, especially with focus on launching generic products. This is owing to high incidence of cancer in the region and regulatory reforms for development and registration of biosimilars. For instance, according to the World Health Organization, the number of new cancer cases diagnosed per year in Africa is expected to grow from over 1 million in 2018 to over 2.1 million in 2040. Moreover, in August 2014, Medicines Control Council of South Africa amended guidelines for the development and registration of biosimilars in South Africa to include requirements for registering monoclonal antibody biosimilars.
Key Takeaways:
The monoclonal antibodies sub segment in the drug type segment in global antibodies market was valued at US$ 124,936.8 Mn in 2018 and is expected to reach US$ 367,264.6 Mn by 2027 at a CAGR of 12.6% during the forecast period.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2629
Increasing approval and robust pipeline of novel human monoclonal antibodies is expected to aid in the segment growth. In the years 2014-2018, highest number of monoclonal antibodies (i.e. 6) were approved in the U.S. in 2018 and Europe witnessed highest number of monoclonal antibodies (i.e. 8) approval in 2017. Out of 8 approvals in Europe in 2017, 4 were biosimilar versions of Humira (adalimumab).
The cancer sub segment in disease indication segment held dominant position in the global antibodies market in 2018, accounting for 54.8% share in terms of value.
High prevalence of cancer and frequent approval and launch of novel monoclonal antibodies in the market is expected to significantly drive growth of the cancer segment over the forecast period. During the past five years (2014-2018), highest number of monoclonal antibodies for cancer treatment (i.e. 12) were approved in Europe in 2017. Out of 12 monoclonal antibodies approved in Europe for cancer treatment in 2017, 6 were biosimilar versions of Roche’s Rituxan (rituximab).
The hospitals sub segment in end user segment held dominant position in the global antibodies market in 2018, accounting for 86.4% share in terms of value, followed by long term care facilities, and research institutes, respectively.
Hospitals segment is expected to gain major market share in the global monoclonal antibodies as cancers drugs such as Herceptin, Avastin, and Rituxan need to be administered in hospitals.
Market Trends
The market is witnessing increasing development of site-specific drug conjugation that are based on introducing selectively reactive molecules at specific locations along the monoclonal antibodies. The approach enhances the therapeutic window of ADCs and reduces toxicity. Some of the widely used site-specific drug conjugation techniques include, conjugation via novel unpaired cysteine residues conjugation via transglutaminases and, conjugation via unnatural amino acids.
Major players in the market are also focused on introducing highly validated conjugated antibodies. For instance, in January 2020, Proteintech Group, an antibody manufacturer, launched over 500 antibodies directly conjugated with high-performance CoraLite488 and CoraLite594 dyes.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/antibodies-market-2703
Regulations
Europe
- In the European Union (EU), biological products including therapeutic monoclonal antibodies are subject to the approval from European Medicines Agency (EMA) through centralized procedure
- Manufacturers of all the biological products are required to get the marketing authorization application (MAA) prior to the marketing of any biological drugs in the European market
- Centralized MAA for biological products obtained under Regulation (EC) No 726/2004 of the European Parliament And Of The Council allows the applicant to market their product in all the 27 member countries
- For biological drugs which have got orphan drug designation should obtain MAA as per Regulation (EC) No 141/2000 of the European Parliament And Of The Council
- For the development of biosimilar biologics, EMA released a guideline for regulatory approval of similar biologics in 2005
Global Antibodies Market: Competitive Landscape
Major players operating in the global antibodies market include, Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.
Global Antibodies Market: Key Developments
- In January 2020, Iovance Biotherapeutics, Inc. obtained a license from Novartis to develop and commercialize an antibody cytokine engrafted protein, referred to as IOV-3001
- In December 2019, Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. submitted a supplemental Biologics License Application for Crysvita (burosumab) – a recombinant fully human monoclonal IgG1 antibody indicated for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized – to the U.S. Food and Drug Administration.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2629
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By End User
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Technological Advancement
- Regulatory Scenario
- Market Dynamics
- Global Antibodies Market, By Drug Type, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- Monoclonal Antibodies
- Polyclonal Antibodies
- Antibody-drug complexes (ADCs)
- Introduction
- Global Antibodies Market, By Disease Indication, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- Introduction
- Global Antibodies Market, By End User, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- Hospitals
- Long-term Care Facilities
- Research institutes
- Introduction
- Global Antibodies Market, By Regions, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Sanofi S.A.
- Eli Lilly and Co.
- Iovance Biotherapeutics, Inc.
- Ultragenyx Pharmaceutical Inc.
- Kyowa Kirin Co., Ltd.
- Novartis International AG
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837